Zomedica Corp. [ZOM] is -17.78% lower this YTD. Is it still time to buy?


Zomedica Corp. [AMEX: ZOM] loss -4.18% or -0.01 points to close at $0.25 with a heavy trading volume of 15405277 shares. The company report on July 7, 2022 that Zomedica Announces New Global Manufacturing & Distribution Center.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


Zomedica Corp. (NYSE American:ZOM) (“Zomedica” or the “Company”), a veterinary health company offering diagnostic and therapeutic products for companion animals, is expanding its manufacturing and distribution facility in Roswell Georgia, which will significantly increase capacity for production and distribution of its products.

“Our PulseVet and TRUFORMA product sales are growing, and we are adding Revo2 and VetGuardian products to the mix. To fulfill customer demand for our expanding portfolio of products with sufficient production and efficient distribution we are committed to expanding our manufacturing capacity and capabilities,” said Larry Heaton, Zomedica’s Chief Executive Officer. “That is reflected in the new Zomedica Global Manufacturing & Distribution Center.”.

It opened the trading session at $0.26, the shares rose to $0.27 and dropped to $0.25, the range by which the price of stock traded the whole day. The daily chart for ZOM points out that the company has recorded -28.41% loss over the past six months. However, it is still -47.06% lower than its most recent low trading price.

If we look at the average trading volume of 22.86M shares, ZOM reached to a volume of 15405277 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here is what top equities market gurus are saying about Zomedica Corp. [ZOM]:

The Average True Range (ATR) for Zomedica Corp. is set at 0.02, with the Price to Sales ratio for ZOM stock in the period of the last 12 months amounting to 32.62. The Price to Book ratio for the last quarter was 0.93, with the Price to Cash per share for the same quarter was set at 0.19.

Trading performance analysis for ZOM stock

Zomedica Corp. [ZOM] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -3.04. With this latest performance, ZOM shares gained by 15.02% in over the last four-week period, additionally sinking by -28.41% over the last 6 months – not to mention a drop of -58.55% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ZOM stock in for the last two-week period is set at 51.73, with the RSI for the last a single of trading hit 51.83, and the three-weeks RSI is set at 50.86 for Zomedica Corp. [ZOM]. The present Moving Average for the last 50 days of trading for this stock 0.2395, while it was recorded at 0.2596 for the last single week of trading, and 0.3421 for the last 200 days.

Zomedica Corp. [ZOM]: A deeper dive into fundamental analysis

Operating Margin for any stock indicates how profitable investing would be, and Zomedica Corp. [ZOM] shares currently have an operating margin of -517.14 and a Gross Margin at +46.32. Zomedica Corp.’s Net Margin is presently recorded at -444.78.

Return on Equity for this stock declined to -11.01, with Return on Assets sitting at -10.61.

Zomedica Corp.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 47.30 and a Current Ratio set at 48.20.

An analysis of insider ownership at Zomedica Corp. [ZOM]

There are presently around $29 million, or 13.30% of ZOM stock, in the hands of institutional investors. The top three institutional holders of ZOM stocks are: VANGUARD GROUP INC with ownership of 40,607,143, which is approximately -2.47% of the company’s market cap and around 2.56% of the total institutional ownership; STATE STREET CORP, holding 18,717,694 shares of the stock with an approximate value of $4.72 million in ZOM stocks shares; and BLACKROCK INC., currently with $3.38 million in ZOM stock with ownership of nearly 5.57% of the company’s market capitalization.

Positions in Zomedica Corp. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 38 institutional holders increased their position in Zomedica Corp. [AMEX:ZOM] by around 4,216,642 shares. Additionally, 44 investors decreased positions by around 15,879,849 shares, while 40 investors held positions by with 93,728,856 shares. The mentioned changes placed institutional holdings at 113,825,347 shares, according to the latest SEC report filing. ZOM stock had 17 new institutional investments in for a total of 1,135,010 shares, while 19 institutional investors sold positions of 2,748,927 shares during the same period.